Lyra Therapeutics (LYRA) Misses Q2 EPS by 41c

Lyra Therapeutics (NASDAQ: LYRA) reported Q2 EPS of ($0.74), $0.41 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $598 thousand versus the consensus estimate of $342.4 thousand.

For earnings history and earnings-related data on Lyra Therapeutics (LYRA) click here.

You May Also Be Interested In

• loanDepot receives NYSE non-compliance notice over stock price
• Solowin Holdings marks 10 years, expands into stablecoins and AI
• Boeing names Ryan Shedd as new SVP and controller